Humacyte, Inc.
HUMA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $275 | $325 | $225 | $598 |
| - Cash | $19 | $38 | $63 | $45 |
| + Debt | $30 | $84 | $16 | $17 |
| Enterprise Value | $286 | $371 | $178 | $570 |
| Revenue | $1 | $0 | $1 | $7 |
| % Growth | 150.2% | -41.8% | -92.8% | – |
| Gross Profit | $0 | -$2 | -$1 | $4 |
| % Margin | 65.5% | -588.7% | -282.8% | 50% |
| EBITDA | -$13 | -$33 | $44 | -$17 |
| % Margin | -1,730.8% | -11,047.5% | 8,505% | -230% |
| Net Income | -$18 | -$38 | $39 | -$21 |
| % Margin | -2,325.4% | -12,511% | 7,570.4% | -289.7% |
| EPS Diluted | -0.11 | -0.24 | 0.28 | -0.16 |
| % Growth | 54.2% | -185.7% | 275% | – |
| Operating Cash Flow | -$24 | -$26 | -$29 | -$27 |
| Capital Expenditures | -$0 | -$1 | -$0 | -$0 |
| Free Cash Flow | -$24 | -$27 | -$29 | -$27 |